News & Updates

Transcutaneous neuromodulation improves symptoms in functional dyspepsia

29 Nov 2023

Patients with functional dyspepsia (FD) may benefit from transcutaneous neuromodulation (TN) treatment, which can significantly improve symptoms and quality of life, according to a study.

Transcutaneous neuromodulation improves symptoms in functional dyspepsia

29 Nov 2023

Continuous vs intermittent feeding: Which is better for critically ill patients?

29 Nov 2023 by

Continuous feeding appears to be more effective than intermittent feeding in reducing the rate of mortality in critically ill patients in the intensive care unit (ICU), reveals a study.

Continuous vs intermittent feeding: Which is better for critically ill patients?

29 Nov 2023

Givosiran delivers safe, sustained improvements in acute hepatic porphyria

28 Nov 2023 by

Long-term monthly treatment with givosiran has good tolerability and offers continuous improvements to patients with acute hepatic porphyria (AHP), results of the phase III ENVISION trial have shown.

Givosiran delivers safe, sustained improvements in acute hepatic porphyria

28 Nov 2023

Biologic dose optimization not needed in UC patients with early nonresponse, high drug clearance

27 Nov 2023

For patients with ulcerative colitis who are receiving vedolizumab, dose optimization may not be required in the presence of early nonresponse to treatment as well as high drug clearance, according to data from the phase IV ENTERPRET study.

Biologic dose optimization not needed in UC patients with early nonresponse, high drug clearance

27 Nov 2023

Palliative care in cancer: Which central venous access devices are associated with higher complication rates?

27 Nov 2023 by

A systematic review and meta-analysis by researchers from the University of Hong Kong has shown that the use of peripherally inserted central catheters (PICCs) is associated with a higher rate of complications than central lines in terminally ill cancer patients with central venous access devices (CVADs) for palliative care. No conclusions were reached regarding the use of totally implanted ports (PORTs), as no studies on PORTs were eligible for analysis.

Palliative care in cancer: Which central venous access devices are associated with higher complication rates?

27 Nov 2023

Novel tri-agonist confers significant gains for MASLD patients

24 Nov 2023 by

In a substudy of a phase II obesity trial, individuals with MASLD* and obesity benefited significantly from retatrutide, a once-weekly, injectable, novel synthetic molecule that has shown potent agonist action at GIP**, GLP-1***, and glucagon receptors.

Novel tri-agonist confers significant gains for MASLD patients

24 Nov 2023

Cholecystectomy during pregnancy supported in large study

24 Nov 2023

For expectant mothers with acute cholecystitis (AC), undergoing cholecystectomy lowers the risk of adverse pregnancy outcomes, according to a large study.

Cholecystectomy during pregnancy supported in large study

24 Nov 2023

Bulevirtide-PegIFNα combo yields benefits for CHD patients

21 Nov 2023 by

A combination regimen comprising bulevirtide 10 mg (BLV10) and pegylated interferon alpha-2a (PegIFNα) improved multiple liver parameters in patients with chronic hepatitis delta (CHD), findings from the phase IIb MYR204 study have shown.

Bulevirtide-PegIFNα combo yields benefits for CHD patients

21 Nov 2023

Semaglutide reduces CV risk in overweight/obese patients without T2D

21 Nov 2023 by

Treatment with semaglutide reduced the risk of major adverse cardiovascular events (MACE) among overweight/obese patients with pre-existing cardiovascular (CV) disease but without type 2 diabetes (T2D), according to the SELECT trial presented at AHA 2023.

Semaglutide reduces CV risk in overweight/obese patients without T2D

21 Nov 2023

8-week TAF course enough to prevent mother–child HBV transmission

20 Nov 2023 by

An 8-week course is as good as a 12-week course of tenofovir alafenamide fumarate (TAF) therapy in terms of preventing the transmission of hepatitis B virus (HBV) infection from mothers to infants, as reported in a study.

8-week TAF course enough to prevent mother–child HBV transmission

20 Nov 2023

News & Updates

Filter by Specialty:

Specialty:

Transcutaneous neuromodulation improves symptoms in functional dyspepsia

Transcutaneous neuromodulation improves symptoms in functional dyspepsia

Continuous vs intermittent feeding: Which is better for critically ill patients?

Continuous vs intermittent feeding: Which is better for critically ill patients?

Givosiran delivers safe, sustained improvements in acute hepatic porphyria

Givosiran delivers safe, sustained improvements in acute hepatic porphyria

Biologic dose optimization not needed in UC patients with early nonresponse, high drug clearance

Biologic dose optimization not needed in UC patients with early nonresponse, high drug clearance

Palliative care in cancer: Which central venous access devices are associated with higher complication rates?

Palliative care in cancer: Which central venous access devices are associated with higher complication rates?

Novel tri-agonist confers significant gains for MASLD patients

Novel tri-agonist confers significant gains for MASLD patients

Cholecystectomy during pregnancy supported in large study

Cholecystectomy during pregnancy supported in large study

Bulevirtide-PegIFNα combo yields benefits for CHD patients

Bulevirtide-PegIFNα combo yields benefits for CHD patients

Semaglutide reduces CV risk in overweight/obese patients without T2D

Semaglutide reduces CV risk in overweight/obese patients without T2D

8-week TAF course enough to prevent mother–child HBV transmission

8-week TAF course enough to prevent mother–child HBV transmission